Bionano Genomics (BNGO) Stock Analysis & AI Equity Report

Medical - Diagnostics & Research USD Explore free reports

Bionano Genomics (BNGO) overview

Bionano Genomics (BNGO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 28.5m and operating profit of USD -33.3m; the year-end share price was 1.53 USD and market capitalisation was USD 16.4m. Bionano Genomics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bionano Genomics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 44.4mFY 2025
Share price1.53 USDFY 2025 year end
RevenueUSD 28.5mFY 2025
Operating profitUSD -33.3mFY 2025
Net earningsUSD -26.4mFY 2025
Market capitalisationUSD 16.4mFY 2025 year end

About Bionano Genomics

Bionano Genomics provides genome analysis solutions for research and clinical applications. Its offerings include optical genome mapping systems, nucleic acid extraction and purification instruments and consumables, genomic analysis software, and OGM-based diagnostic and laboratory services. Researchers, clinicians and laboratories use its products and services to analyze genomic data and investigate structural variation in areas including genetic disease, cancer and cell and gene therapy.

Generate the Bionano Genomics report

Bionano Genomics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Bionano Genomics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Bionano Genomics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.